Results 171 to 180 of about 768,066 (299)

Cutaneous melanoma [PDF]

British Journal of Cancer, 2001
Négrier, S, Fervers, B, Bailly, C, Beckendorf, V, Cupissol, D, Doré, J F, Dorval, T, Garbay, J R, Vilmer, C   +8 more
openaire   +2 more sources

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

Advanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang, Xiaoyan Yin, Ting Wang, Hongfu Zhao, Zhipeng Zhao, Jinbao Wang, Cheng Tao, Xuanchu Ge, Yanze Li, Linlin Liu, Fuxin Xue   +10 more
wiley   +1 more source

Epigenetics of Malignant Melanoma: Mechanisms, Diagnostic Approaches and Therapeutic Applications. [PDF]

Oncol Res
Hong SG, Murphy GF, Lian CG.
europepmc   +1 more source

Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

Advanced Science, EarlyView.
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou, Zhihang Zhou, Houyu Ju, Chaoyang Guo, Fangxing Zhu, Yiyi Zhang, Xu Chen, Tongchao Zhao, Laiping Zhong, Jingzhou Hu   +9 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Cutaneous Melanoma Care in Low-Resource Settings: Surgical Disparities in Global Reconstructive Oncology. [PDF]

Plast Reconstr Surg Glob Open
Omwansa PN, Klopper GJ, Jafta Z, Simpson EJ, Adeniyi VO.   +4 more
europepmc   +1 more source

NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation

Advanced Science, EarlyView.
NIBAN2, highly expressed in glioma stem‐like cells (GSCs), assembles with FLII and transcription factor RREB1 to form a nuclear complex. This complex transcriptionally activates stemness‐associated genes (e.g., CD44, NANOG) and metabolic enzymes (e.g., LDHA), thereby sustaining both transcriptional and metabolic stemness programs.
Liang liang Shi, Xinwei Qiao, Yue Hu, Minjie Wang, Shaojie Yu, Zihan Gong, Yuxin Rao, Hui Zheng, Siting Chen, Lin Li, Rong Fu, Tao Liang, Jin Yao, Xiaobing Jiang, Junjun Li   +14 more
wiley   +1 more source

Insight into the emerging role of long non-coding RNAs in BRAF inhibitor resistance in melanoma. [PDF]

Front Oncol
Yadav V, Jena MK, Singh T, Kumar R, Garg VK.   +4 more
europepmc   +1 more source

DADA Enhances CD8+ T Cell Stemness to Improve Anti‐Tumor Immunity and Immunotherapy Efficacy

Advanced Science, EarlyView.
Diisopropylamine dichloroacetate (DADA) enhances CD8+ T cell stemness by improving OXPHOS and mitochondrial fitness in a PDK1‐depenpendent manner. This metabolic shift strengthens CD8+ T cell anti‐tumor immunity, improves responses to PD‐1 blockade, and endows CAR‐T cells with prolonged persistence and resistance to terminal exhaustion, highlighting a ...
Mingyue Bi, Fei Li, Heng Jiang, Lingling Gu, Mengjie Sun, Kunyu Lu, Pianpian Liu, Ruyue Xie, Wenqiang Ma, Meijuan Zheng, Xianwei Wang, Xuefu Wang, Jingjing Cong   +12 more
wiley   +1 more source

Advanced Mucosal Melanoma Therapies: Current Status and Future Directions. [PDF]

Curr Treat Options Oncol
Zhang Y, Zhao D, Wu D.
europepmc   +1 more source